Genetically determined telomere length and risk for haematologic diseases: results from large prospective cohorts and Mendelian Randomization analysis

Category	Detail
Condition	Hematologic diseases including anemia, lymphoma, leukemia, myeloproliferative diseases, haemostasis and coagulation disorders
Key Mechanisms	Telomere attrition and epigenetic age acceleration (EAA) as molecular aging markers influencing disease risk
Target Population	General population cohorts with genetic data, including UK Biobank and FinnGen participants
Care Setting	Research and clinical genetics settings focusing on hematologic disease risk assessment

Genetically increased telomere length is associated with higher risk of multiple hematologic malignancies including lymphoid leukemia, Hodgkin lymphoma, and multiple myeloma.
Epigenetic age acceleration measures show variable associations; Hannum age acceleration linked to lower chronic myeloid leukemia risk, while PhenoAge acceleration associates with increased risks of myeloid and lymphoid leukemias.
Mendelian randomization analyses confirm telomere length as a causal factor for several hematologic diseases independent of epigenetic aging effects.

Consider genetic assessment of telomere length as part of risk evaluation for hematologic malignancies.
Incorporate epigenetic age acceleration markers cautiously, recognizing variable associations with disease risk.

Monitor individuals with genetically increased telomere length for early signs of hematologic malignancies.
Further research needed before implementing epigenetic age acceleration measures in clinical management.

Use longitudinal genetic and epigenetic data to track risk progression in susceptible populations.
Apply Mendelian randomization findings to refine risk stratification models.

Increased telomere length may elevate risk for specific hematologic cancers.
Epigenetic age acceleration effects on hematologic disease risk are heterogeneous and require further validation.

Individuals with genetic predisposition to altered telomere length and epigenetic aging profiles

No direct treatment recommendations; findings support genetic risk stratification to guide surveillance and early intervention strategies.

Utilize Mendelian randomization to clarify causal relationships between aging biomarkers and hematologic diseases.
Validate genetic associations in independent cohorts before clinical application.
Integrate genetic and epigenetic data for comprehensive hematologic disease risk assessment.

Clinical Scorecard: Inherited telomere length and its association with hematologic disorders: findings from extensive prospective studies and Mendelian Randomization analysis